A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer
Part of paid clinical trials in Decatur, Illinois.
- Sponsor
- Cell>Point LLC
- Study ID
- NCT01394679
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose) — DRUGOne injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
- 18 F FDG followed by PET/CT imaging — DRUGSingle injection of 18 F FDG range of 10-20 mCi
Study Details
The purpose of this study is to determine if the images of the primary lesions of lung cancer and any metastatic lesions seen from the investigational SPECT/CT 99mTC-EC-DG scans are the same as the PET/CT 18F-FDG scans.
Key Dates
- Start date
- May 1, 2025
- Status verified
- Mar 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 154 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- DIAGNOSTIC
Arms
- Active Comparator: 18-F-FDG Imaging Agent18 F FDG followed by PET/CT imaging
- Experimental: 99m Tc-EC-DG imaging agent99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and \< 1 mg EC-DG
Primary Outcome Measure
Efficacy:Comparison of 99mTc-EcC-DG SPECT/CT images to 18F-FDG PET/CT images of primary lung cancer lesion and metastatic lesions [ Time Frame: Images will be compared at the core image lab at approximately every 4 to 6 weeks ]
Central Contacts
- Greg Colip, JD281-288-4643
- Cynthia Phurrough, BS513-618-0337
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Decatur Memorial Hospital | Decatur | Illinois | 62526 | - |
Find similar trials in Decatur, IL
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung CancerPHASE2/PHASE3 · Recruiting · Canadian Cancer Trials Group · Chicago, Illinois
- Prolonged Air Leak (PAL) Autologous Blood Patch Intervention TrialEnrolling By Invitation · Rush University Medical Center · Chicago, Illinois
- Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)PHASE2 · Recruiting · University of Chicago · Chicago, Illinois